AbbVie (NYSE:ABBV) Trading Down 1.5% After Insider Selling

Key Points

• AbbVie shares fell 1.5% to $261.88 after Executive Vice President Nicholas Donoghoe sold 32,710 shares for approximately $8.18 million, reducing his position by 30.53%.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $275.95; recent targets range as high as $300.
• AbbVie exceeded quarterly expectations with $3.65 EPS and $16.99 billion in revenue, while maintaining a quarterly dividend of $1.73 per share, equivalent to a 2.6% annualized yield.

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) dropped 1.5% on Thursday following insider selling activity. The company traded as low as $260.48 and last traded at $261.88. 5,125,653 shares were traded during trading, a decline of 25% from the average session volume of 6,870,330 shares. The stock had previously closed at $265.97.

Specifically, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ABBV shares. DZ Bank upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Guggenheim upped their price target on shares of AbbVie from $261.00 to $288.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Wells Fargo & Company increased their price target on AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a report on Monday. HSBC reissued a "buy" rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Finally, UBS Group upped their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $275.95.

AbbVie Trading Down 1.5%

The firm has a market cap of $462.69 billion, a P/E ratio of 73.98, a PEG ratio of 0.86 and a beta of 0.30. The company's 50-day moving average is $246.98 and its two-hundred day moving average is $226.95.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie's dividend payout ratio is presently 195.48%.

Institutional Investors Weigh In On AbbVie

Institutional investors have recently made changes to their positions in the stock. Advocacy Wealth Management LLC lifted its holdings in AbbVie by 3.9% during the 2nd quarter. Advocacy Wealth Management LLC now owns 3,814 shares of the company's stock worth $960,000 after purchasing an additional 143 shares in the last quarter. CTC Alternative Strategies Ltd. purchased a new position in AbbVie during the 2nd quarter valued at about $2,869,000. M Holdings Securities Inc. increased its position in shares of AbbVie by 3.9% during the second quarter. M Holdings Securities Inc. now owns 23,422 shares of the company's stock valued at $5,664,000 after buying an additional 887 shares during the period. Oarsman Capital Inc. increased its position in shares of AbbVie by 3.4% during the second quarter. Oarsman Capital Inc. now owns 20,266 shares of the company's stock valued at $5,100,000 after buying an additional 668 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in shares of AbbVie in the second quarter worth about $3,478,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source